Maia Biotechnology Revenue and Competitors
Estimated Revenue & Valuation
- Maia Biotechnology's estimated annual revenue is currently $4M per year.
- Maia Biotechnology's estimated revenue per employee is $155,000
Employee Data
- Maia Biotechnology has 26 Employees.
- Maia Biotechnology grew their employee count by -24% last year.
Maia Biotechnology Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.3M | 28 | 56% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $2M | 13 | 0% | N/A | N/A |
#4 | $654.7M | 2640 | 29% | $1.1B | N/A |
#5 | $1.7M | 11 | 57% | N/A | N/A |
#6 | $28.7M | 185 | 25% | N/A | N/A |
#7 | $2.8M | 18 | 64% | N/A | N/A |
#8 | $1.9M | 12 | 33% | N/A | N/A |
#9 | $1.7M | 11 | 57% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Maia Biotechnology?
MAIA Biotechnology, Inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. MAIA's business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. MAIA controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. MAIA's business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure, management team, and resources of the MAIA enterprise. This model allows MAIA to provide more focused R&D support to each drug candidate, while also distributing shared central resources among subsidiary companies to maintain a lean, capital-efficient operating structure.
keywords:N/AN/A
Total Funding
26
Number of Employees
$4M
Revenue (est)
-24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Maia Biotechnology News
MAIA Biotechnology, Inc. Announces FDA Orphan Drug Designation for THIO for the Treatment of Hepatocellular Carcinoma (HCC).
Maia Biotechnology has filed to raise capital via a U.S. IPO. The firm is developing a novel approach to treating various cancers.
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.8M | 26 | -24% | $10M |
#2 | $1.8M | 26 | 8% | $76.5M |
#3 | $2.5M | 26 | N/A | N/A |
#4 | $2.6M | 26 | N/A | N/A |
#5 | $2.6M | 26 | N/A | N/A |